Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study

Niels Kruse, Staffan Persson, Daniel Alcolea, Justyna M C Bahl, Ines Baldeiras, Elisabetta Capello, Davide Chiasserini, Luisella Bocchio Chiavetto, Andreja Emersic, Sebastiaan Engelborghs, Erden Eren, Tormod Fladby, Giovanni Frisoni, María Salud García-Ayllón, Sermin Genc, Olymbia Gkatzima, Niels H H Heegaard, André M. Janeiro, Branislav Kováčech, H. Bea KuiperijMaria J. Leitão, Alberto Lleó, Madalena Martins, Mafalda Matos, Hanne M. Mollergard, Flavio Nobili, Annika Öhrfelt, Lucilla Parnetti, Catarina Resende de Oliveira, Uros Rot, Javier Sáez-Valero, Hanne Struyfs, Julia T. Tanassi, Peggy Taylor, Magda Tsolaki, Eugeen Vanmechelen, Marcel M. Verbeek, Norbert Zilka, Kaj Blennow, Henrik Zetterberg, Brit Mollenhauer

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Decreased levels of alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) in Parkinson's disease and related synucleinopathies have been reported, however, not consistently in all cross-sectional studies. To test the performance of one recently released human-specific enzyme-linked immunosorbent assay (ELISA) for the quantification of aSyn in CSF, we carried out a round robin trial with 18 participating laboratories trained in CSF ELISA analyses within the BIOMARKAPD project in the EU Joint Program - Neurodegenerative Disease Research. CSF samples (homogeneous aliquots from pools) and ELISA kits (one lot) were provided centrally and data reported back to one laboratory for data analysis. Our study showed that although factors such as preanalytical sample handling and lot-to-lot variability were minimized by our study design, we identified high variation in absolute values of CSF aSyn even when the same samples and same lots of assays were applied. We further demonstrate that although absolute concentrations differ between laboratories the quantitative results are comparable. With further standardization this assay may become an attractive tool for comparing aSyn measurements in diverse settings. Recommendations for further validation experiments and improvement of the interlaboratory results obtained are given.

Original languageEnglish
Pages (from-to)2587-2596
Number of pages10
JournalNeurobiology of Aging
Volume36
Issue number9
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

alpha-Synuclein
Cerebrospinal Fluid
Enzyme-Linked Immunosorbent Assay
Songbirds
Neurodegenerative Diseases
Parkinson Disease
Cross-Sectional Studies
Research

Keywords

  • Alpha-synuclein
  • Biomarker
  • Cerebrospinal fluid
  • ELISA
  • Validation

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Ageing
  • Developmental Biology
  • Geriatrics and Gerontology

Cite this

Kruse, N., Persson, S., Alcolea, D., Bahl, J. M. C., Baldeiras, I., Capello, E., ... Mollenhauer, B. (2015). Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 36(9), 2587-2596. https://doi.org/10.1016/j.neurobiolaging.2015.05.003

Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. / Kruse, Niels; Persson, Staffan; Alcolea, Daniel; Bahl, Justyna M C; Baldeiras, Ines; Capello, Elisabetta; Chiasserini, Davide; Bocchio Chiavetto, Luisella; Emersic, Andreja; Engelborghs, Sebastiaan; Eren, Erden; Fladby, Tormod; Frisoni, Giovanni; García-Ayllón, María Salud; Genc, Sermin; Gkatzima, Olymbia; Heegaard, Niels H H; Janeiro, André M.; Kováčech, Branislav; Kuiperij, H. Bea; Leitão, Maria J.; Lleó, Alberto; Martins, Madalena; Matos, Mafalda; Mollergard, Hanne M.; Nobili, Flavio; Öhrfelt, Annika; Parnetti, Lucilla; de Oliveira, Catarina Resende; Rot, Uros; Sáez-Valero, Javier; Struyfs, Hanne; Tanassi, Julia T.; Taylor, Peggy; Tsolaki, Magda; Vanmechelen, Eugeen; Verbeek, Marcel M.; Zilka, Norbert; Blennow, Kaj; Zetterberg, Henrik; Mollenhauer, Brit.

In: Neurobiology of Aging, Vol. 36, No. 9, 01.09.2015, p. 2587-2596.

Research output: Contribution to journalArticle

Kruse, N, Persson, S, Alcolea, D, Bahl, JMC, Baldeiras, I, Capello, E, Chiasserini, D, Bocchio Chiavetto, L, Emersic, A, Engelborghs, S, Eren, E, Fladby, T, Frisoni, G, García-Ayllón, MS, Genc, S, Gkatzima, O, Heegaard, NHH, Janeiro, AM, Kováčech, B, Kuiperij, HB, Leitão, MJ, Lleó, A, Martins, M, Matos, M, Mollergard, HM, Nobili, F, Öhrfelt, A, Parnetti, L, de Oliveira, CR, Rot, U, Sáez-Valero, J, Struyfs, H, Tanassi, JT, Taylor, P, Tsolaki, M, Vanmechelen, E, Verbeek, MM, Zilka, N, Blennow, K, Zetterberg, H & Mollenhauer, B 2015, 'Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study', Neurobiology of Aging, vol. 36, no. 9, pp. 2587-2596. https://doi.org/10.1016/j.neurobiolaging.2015.05.003
Kruse, Niels ; Persson, Staffan ; Alcolea, Daniel ; Bahl, Justyna M C ; Baldeiras, Ines ; Capello, Elisabetta ; Chiasserini, Davide ; Bocchio Chiavetto, Luisella ; Emersic, Andreja ; Engelborghs, Sebastiaan ; Eren, Erden ; Fladby, Tormod ; Frisoni, Giovanni ; García-Ayllón, María Salud ; Genc, Sermin ; Gkatzima, Olymbia ; Heegaard, Niels H H ; Janeiro, André M. ; Kováčech, Branislav ; Kuiperij, H. Bea ; Leitão, Maria J. ; Lleó, Alberto ; Martins, Madalena ; Matos, Mafalda ; Mollergard, Hanne M. ; Nobili, Flavio ; Öhrfelt, Annika ; Parnetti, Lucilla ; de Oliveira, Catarina Resende ; Rot, Uros ; Sáez-Valero, Javier ; Struyfs, Hanne ; Tanassi, Julia T. ; Taylor, Peggy ; Tsolaki, Magda ; Vanmechelen, Eugeen ; Verbeek, Marcel M. ; Zilka, Norbert ; Blennow, Kaj ; Zetterberg, Henrik ; Mollenhauer, Brit. / Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. In: Neurobiology of Aging. 2015 ; Vol. 36, No. 9. pp. 2587-2596.
@article{a08617d029f8498da7b2f0e93efa665a,
title = "Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study",
abstract = "Decreased levels of alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) in Parkinson's disease and related synucleinopathies have been reported, however, not consistently in all cross-sectional studies. To test the performance of one recently released human-specific enzyme-linked immunosorbent assay (ELISA) for the quantification of aSyn in CSF, we carried out a round robin trial with 18 participating laboratories trained in CSF ELISA analyses within the BIOMARKAPD project in the EU Joint Program - Neurodegenerative Disease Research. CSF samples (homogeneous aliquots from pools) and ELISA kits (one lot) were provided centrally and data reported back to one laboratory for data analysis. Our study showed that although factors such as preanalytical sample handling and lot-to-lot variability were minimized by our study design, we identified high variation in absolute values of CSF aSyn even when the same samples and same lots of assays were applied. We further demonstrate that although absolute concentrations differ between laboratories the quantitative results are comparable. With further standardization this assay may become an attractive tool for comparing aSyn measurements in diverse settings. Recommendations for further validation experiments and improvement of the interlaboratory results obtained are given.",
keywords = "Alpha-synuclein, Biomarker, Cerebrospinal fluid, ELISA, Validation",
author = "Niels Kruse and Staffan Persson and Daniel Alcolea and Bahl, {Justyna M C} and Ines Baldeiras and Elisabetta Capello and Davide Chiasserini and {Bocchio Chiavetto}, Luisella and Andreja Emersic and Sebastiaan Engelborghs and Erden Eren and Tormod Fladby and Giovanni Frisoni and Garc{\'i}a-Ayll{\'o}n, {Mar{\'i}a Salud} and Sermin Genc and Olymbia Gkatzima and Heegaard, {Niels H H} and Janeiro, {Andr{\'e} M.} and Branislav Kov{\'a}čech and Kuiperij, {H. Bea} and Leit{\~a}o, {Maria J.} and Alberto Lle{\'o} and Madalena Martins and Mafalda Matos and Mollergard, {Hanne M.} and Flavio Nobili and Annika {\"O}hrfelt and Lucilla Parnetti and {de Oliveira}, {Catarina Resende} and Uros Rot and Javier S{\'a}ez-Valero and Hanne Struyfs and Tanassi, {Julia T.} and Peggy Taylor and Magda Tsolaki and Eugeen Vanmechelen and Verbeek, {Marcel M.} and Norbert Zilka and Kaj Blennow and Henrik Zetterberg and Brit Mollenhauer",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.neurobiolaging.2015.05.003",
language = "English",
volume = "36",
pages = "2587--2596",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study

AU - Kruse, Niels

AU - Persson, Staffan

AU - Alcolea, Daniel

AU - Bahl, Justyna M C

AU - Baldeiras, Ines

AU - Capello, Elisabetta

AU - Chiasserini, Davide

AU - Bocchio Chiavetto, Luisella

AU - Emersic, Andreja

AU - Engelborghs, Sebastiaan

AU - Eren, Erden

AU - Fladby, Tormod

AU - Frisoni, Giovanni

AU - García-Ayllón, María Salud

AU - Genc, Sermin

AU - Gkatzima, Olymbia

AU - Heegaard, Niels H H

AU - Janeiro, André M.

AU - Kováčech, Branislav

AU - Kuiperij, H. Bea

AU - Leitão, Maria J.

AU - Lleó, Alberto

AU - Martins, Madalena

AU - Matos, Mafalda

AU - Mollergard, Hanne M.

AU - Nobili, Flavio

AU - Öhrfelt, Annika

AU - Parnetti, Lucilla

AU - de Oliveira, Catarina Resende

AU - Rot, Uros

AU - Sáez-Valero, Javier

AU - Struyfs, Hanne

AU - Tanassi, Julia T.

AU - Taylor, Peggy

AU - Tsolaki, Magda

AU - Vanmechelen, Eugeen

AU - Verbeek, Marcel M.

AU - Zilka, Norbert

AU - Blennow, Kaj

AU - Zetterberg, Henrik

AU - Mollenhauer, Brit

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Decreased levels of alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) in Parkinson's disease and related synucleinopathies have been reported, however, not consistently in all cross-sectional studies. To test the performance of one recently released human-specific enzyme-linked immunosorbent assay (ELISA) for the quantification of aSyn in CSF, we carried out a round robin trial with 18 participating laboratories trained in CSF ELISA analyses within the BIOMARKAPD project in the EU Joint Program - Neurodegenerative Disease Research. CSF samples (homogeneous aliquots from pools) and ELISA kits (one lot) were provided centrally and data reported back to one laboratory for data analysis. Our study showed that although factors such as preanalytical sample handling and lot-to-lot variability were minimized by our study design, we identified high variation in absolute values of CSF aSyn even when the same samples and same lots of assays were applied. We further demonstrate that although absolute concentrations differ between laboratories the quantitative results are comparable. With further standardization this assay may become an attractive tool for comparing aSyn measurements in diverse settings. Recommendations for further validation experiments and improvement of the interlaboratory results obtained are given.

AB - Decreased levels of alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) in Parkinson's disease and related synucleinopathies have been reported, however, not consistently in all cross-sectional studies. To test the performance of one recently released human-specific enzyme-linked immunosorbent assay (ELISA) for the quantification of aSyn in CSF, we carried out a round robin trial with 18 participating laboratories trained in CSF ELISA analyses within the BIOMARKAPD project in the EU Joint Program - Neurodegenerative Disease Research. CSF samples (homogeneous aliquots from pools) and ELISA kits (one lot) were provided centrally and data reported back to one laboratory for data analysis. Our study showed that although factors such as preanalytical sample handling and lot-to-lot variability were minimized by our study design, we identified high variation in absolute values of CSF aSyn even when the same samples and same lots of assays were applied. We further demonstrate that although absolute concentrations differ between laboratories the quantitative results are comparable. With further standardization this assay may become an attractive tool for comparing aSyn measurements in diverse settings. Recommendations for further validation experiments and improvement of the interlaboratory results obtained are given.

KW - Alpha-synuclein

KW - Biomarker

KW - Cerebrospinal fluid

KW - ELISA

KW - Validation

UR - http://www.scopus.com/inward/record.url?scp=84940467315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940467315&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2015.05.003

DO - 10.1016/j.neurobiolaging.2015.05.003

M3 - Article

C2 - 26093515

AN - SCOPUS:84940467315

VL - 36

SP - 2587

EP - 2596

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 9

ER -